MT-II treatment, n = 8)
Tirzepatide (Mounjaro, Zepbound) Strengths: Highest efficacy for both glucose control and weight loss Dual mechanism (GLP-1 + GIP) may provide unique benefits Once-weekly dosing Generally well-tolerated Considerations: Higher cost than semaglutide Less long-term safety data (newer medication) Cardiovascular outcome trial not yet complete (though expected to be positive) Best for: Patients prioritizing maximum weight loss
Once a day, place one sheet to the ceiling of your mouth and slowly let it melt into your mouth
No completed randomized controlled human trial
Feb 5, 2026 Feb 5, 2026 Semaglutide withdrawal symptoms: what to expect when you stop Semaglutide withdrawal symptoms: what to expect when you stop Feb 5, 2026 Feb 5, 2026 Retatrutide dose schedule: complete week-by-week titration guide Retatrutide dose schedule: complete week-by-week titration guide Feb 5, 2026 Feb 5, 2026 Retatrutide dose: the complete guide to dosing protocols, titration, and results Retatrutide dose: the complete guide to dosing protocols, titration, and results Feb 5, 2026 Feb 5, 2026 How many mg is 40 units of semaglutide: complete conversion guide How many mg is 40 units of semaglutide: complete conversion guide Feb 5, 2026 Feb 5, 2026 How long does it take for tirzepatide to suppress appetite

Certificado de anlisis por lote Lotes de Retatrutida con certificado de anlisis publicado en el catlogo de COA: Lote EXO010626027A 30 mg, emitido 2026-05-21 Lote EXO010626027B 15 mg, emitido 2026-05-22 Lote EXO010626027C 5 mg, emitido 2026-05-25 Lote EXO010626027D 10 mg, emitido 2026-05-22 Lote EXO010626027E 40 mg, emitido 2026-05-21 Lote EXO010626027F 50 mg, emitido 2026-05-23 Lote EXO010626027G 60 mg, emitido 2026-05-19 Lote EXO010626027H 20 mg, emitido 2026-05-27 Lote EXO010626027J 100 mg, emitido 2026-05-22 Referencias cientficas (4) Literatura revisada por pares sobre Retatrutida, con su identificador PubMed cuando est disponible: Retatrutide en MASLD Estudio fase 2 (Sanyal AJ, Kaplan LM, Frias JP, et al